Cellectar Biosciences provides update on CLOVER-2 Phase 1 trial

Cellectar Biosciences (CLRB) announced initial results as of June 10, 2025, from the CLOVER-2 Phase 1 clinical trial evaluating iopofosine I 131 in relapsed/refractory pediatric high-grade glioma, pHGG, patients. Rare Pediatric Drug and Orphan Drug Designations for pHGG have previously been granted for iopofosine I 131. Iopofosine I 131 was well tolerated and its toxicity profile was consistent with the Company’s previously reported safety data. Importantly, patients on iopofosine I 131 did not experience any cardiovascular, renal, or liver toxicities, and no peripheral neuropathy or significant bleeding. The safety profile was consistent with selective targeting of tumor sites with clinically negligible off-target effect outside the hematologic system. The most frequently reported treatment emergent adverse events were hematologic in nature and were predictable and manageable. All patients recovered from cytopenias.